





CODE: C000138400

NAME AND ADDRESS:

Test Report Status

Final

SINGRAY KORAH B 502 MANASMOTI APT GOREGAON East

Mumbai 400097 MAHARASHTRA Cert. No. MC-2010

Biological Reference Interval Units

SRL Ltd

PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL

ESTATE, S.V. ROAD, GOREGAON (W)

Mumbai, 400062 MAHARASHTRA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956

PATIENT NAME: SINGRAY KORAH PATIENT ID: SINGM0808782

ACCESSION NO: 0002VK055472 AGE: 44 Years SEX: Male ABHA NO:

DRAWN: 26/11/2022 08:52:50 RECEIVED: 26/11/2022 08:54:36 REPORTED: 29/11/2022 15:05:40

Results

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

METHOD : PHOTOHERIC MEASUREMENT RED BLOOD CELL (RBC) COUNT METHOD : COULTER PRINCIPLE WHITE BLOOD CELL (WBC) COUNT METHOD : COULTER PRINCIPLE WHITE BLOOD CELL (WBC) COUNT METHOD : COULTER PRINCIPLE PLATELET COUNT METHOD : ELECTRONIC IMPEDENCE & MICROSCOPY RBC AND PLATELET INDICES HEMATOCRIT (PCV) 38.0 Low 40.0 - 50.0 % METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR VOLUME (MCV) METHOD : CALCULATED PARAMETER ROM BRC HISTOGRAM MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN METHOD : CALCULATED PARAMETER MED CELL DISTRIBUTION WIDTH (RDW) 13.7 11.6 - 14.0 % METHOD : CALCULATED PARAMETER FROM BRC HISTOGRAM MENTZER INDEX 14.4 MEAN PLATELET VOLUME (MPV) 12.7 High 6.8 - 10.9 #I High 6.8 - 10.9 #I High 6.8 - 10.9 #I HIGH 0: VCSN TECHNOLOGY/ MICROSCOPY WENDOD: VCSN TECHNOLOGY/ MICROSCOPY MONOCYTES 11 High 2.0 - 10.0 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY MONOCYTES 11 High 2.0 - 10.0 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY BASOPHILS 0 - 10 - 0 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY BASOPHILS 0 - 10 - 0 %	BLOOD COUNTS,EDTA WHOLE BLOOD				
RED BLOOD CELL (RBC) COUNT METHOD: COULTER PRINCIPLE WHITE BLOOD CELL (WBC) COUNT METHOD: COULTER PRINCIPLE PLATELET COUNT METHOD: ELECTRONIC IMPEDENCE & MICROSCOPY RBC AND PLATELET INDICES HEMATOCRIT (PCV) METHOD: CALCULATED PARAMETER MEAN CORPUSCULAR VOLUME (MCV) METHOD: CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: DEBYTED PARAMETER MEAN PARAMETER FROM RBC HISTOGRAM METHOD: DEBYTED PARAMETER RED CELL DISTRIBUTION WIDTH (RDW) 13.7 11.6 - 14.0 METHOD: DEBYTED PARAMETER ROM PARE HISTOGRAM METHOD: DEBYTED PARAMETER FROM RBC HISTOGRAM METHOD: DEBYTED PARAMETER ROM PARELET HISTOGRAM METHOD: DEBYTED PARAMETER ROM PARELET HISTOGRAM METHOD: USEN TECHNOLOGY/ MICROSCOPY LYMPHOCYTES 33 20 - 40 METHOD: VCSN TECHNOLOGY/ MICROSCOPY MONOCYTES 11 High 2.0 - 10.0 METHOD: VCSN TECHNOLOGY/ MICROSCOPY METHOD: VCSN TECHNOLOGY/	HEMOGLOBIN (HB)	12.0	Low	13.0 - 17.0	g/dL
METHOD : COULTER PRINCIPLE WHITE BLOOD CELL (WBC) COUNT	METHOD: PHOTOMETRIC MEASUREMENT				
WHITE BLOOD CELL (WBC) COUNT	RED BLOOD CELL (RBC) COUNT	5.14		4.5 - 5.5	mil/μL
METHOD : COULTER PRINCIPLE PLATELET COUNT METHOD : ELECTRONIC IMPEDENCE & MICROSCOPY RBC AND PLATELET INDICES HEMATOCRIT (PCV) METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR VOLUME (MCV) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : DERIVED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR MEAN CORPUSCULAR MEAN CORPUSCULAR METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR MEAN CORPUSCULAR	METHOD : COULTER PRINCIPLE				
PLATELET COUNT METHOD : ELECTRONIC IMPEDENCE & MICROSCOPY RBC AND PLATELET INDICES HEMATOCRIT (PCV) 38.0 Low 40.0 - 50.0 % METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR VOLUME (MCV) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER RED CELL DISTRIBUTION WIDTH (RDW) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM MENTZER INDEX MEAN PLATELET VOLUME (MPV) METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM MEND PLATELET VOLUME (MPV) METHOD : CERIVED PARAMETER FROM PLATELET HISTOGRAM WBC DIFFRENTIAL COUNT NEUTROPHILS METHOD : VCSN TECHNOLOGY/ MICROSCOPY LYMPHOCYTES METHOD : VCSN TECHNOLOGY/ MICROSCOPY MONOCYTES METHOD : VCSN TECHNOLOGY/ MICROSCOPY MONOCYTES METHOD : VCSN TECHNOLOGY/ MICROSCOPY EOSINOPHILS 1 1.0 - 6.0 METHOD : VCSN TECHNOLOGY/ MICROSCOPY EOSINOPHILS 0 0 - 1 0 - 1 %	WHITE BLOOD CELL (WBC) COUNT	3.40	Low	4.0 - 10.0	thou/µL
METHOD : ELECTRONIC IMPEDENCE & MICROSCOPY RBC AND PLATELET INDICES HEMATOCRIT (PCV) 38.0 Low 40.0 - 50.0 % METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR VOLUME (MCV) 73.9 Low 83.0 - 101.0 fL MEAN CORPUSCULAR HEMOGLOBIN (MCH) 23.4 Low 27.0 - 32.0 pg MEAN CORPUSCULAR HEMOGLOBIN (MCH) 31.6 31.5 - 34.5 g/dL CONCENTRATION (MCHC) MEAN CORPUSCULAR HEMOGLOBIN (MCH) 13.7 11.6 - 14.0 % MEAN CORPUSCULAR HEMOGLOBIN (MCH) 13.7 11.6 - 14.0 % METHOD : CALCULATED PARAMETER 14.4 MENTZER INDEX 14.4 MEAN PLATELET VOLUME (MPV) 12.7 High 6.8 - 10.9 fL WINTEREDITION WIDTER (MPV) 12.7 High 6.8 - 10.9	METHOD : COULTER PRINCIPLE				
REC AND PLATELET INDICES HEMATOCRIT (PCV) 38.0 Low 40.0 - 50.0 % METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR VOLLUME (MCV) 73.9 Low 83.0 - 101.0 fL METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM MEAN CORPUSCULAR HEMOGLOBIN (MCH) 23.4 Low 27.0 - 32.0 pg METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN (MCH) 23.4 Low 27.0 - 32.0 pg METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN (MCH) 31.6 31.5 - 34.5 g/dL CONCENTRATION (MCHC) METHOD (MCHC) METHOD (MCHC) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM MENTHOD : DERIVED PARAMETER FROM RBC HISTOGRAM MEAN PLATELET VOLUME (MPV) 12.7 High 6.8 - 10.9 fL METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM MEND DERIVED PARAMETER FROM PLATELET HISTOGRAM WBC DIFFERENTIAL COUNT NEUTROPHILS 55 40 - 80 % METHOD : VCSN TECHNOLOGY/ MICROSCOPY LYMPHOCYTES 33 20 - 40 % METHOD : VCSN TECHNOLOGY/ MICROSCOPY METHOD : VCSN TECHNOLOGY/ MICROSCOPY MONOCYTES 11 High 2.0 - 10.0 % METHOD : VCSN TECHNOLOGY/ MICROSCOPY EOSINOPHILS 1 1.0 - 6.0 % METHOD : VCSN TECHNOLOGY/ MICROSCOPY EOSINOPHILS 1 1.0 - 6.0 % METHOD : VCSN TECHNOLOGY/ MICROSCOPY BASOPHILS 0 0 0 - 1 0 0 9 6	PLATELET COUNT	100	Low	150 - 410	thou/µL
HEMATOCRIT (PCV) 38.0 Low 40.0 - 50.0 % METHOD: CALCULATED PARAMETER MEAN CORPUSCULAR VOLUME (MCV) 73.9 Low 83.0 - 101.0 fL METHOD: DERIVED PARAMETER FROM RBC HISTOGRAM MEAN CORPUSCULAR HEMOGLOBIN (MCH) 23.4 Low 27.0 - 32.0 pg METHOD: CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN (MCH) 31.6 31.5 - 34.5 g/dL CONCENTRATION (MCHC) METHOD: CALCULATED PARAMETER RED CELL DISTRIBUTION WIDTH (RDW) 13.7 11.6 - 14.0 % METHOD: DERIVED PARAMETER FROM RBC HISTOGRAM MENTZER INDEX MEAN PLATELET VOLUME (MPV) 12.7 High 6.8 - 10.9 fL METHOD: DERIVED PARAMETER FROM PLATELET HISTOGRAM WBC DIFFERENTIAL COUNT NEUTROPHILS 55 40 - 80 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY LYMPHOCYTES 33 20 - 40 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY MONOCYTES 11 High 2.0 - 10.0 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY EOSINOPHILS 1 1.0 - 6.0 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY EOSINOPHILS 1 1.0 - 6.0 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY BASOPHILS 0 0 0 - 1 %	METHOD: ELECTRONIC IMPEDENCE & MICROSCOPY				
METHOD : CALCULATED PARAMETER T3.9 Low 83.0 - 101.0 fL MEAN CORPUSCULAR VOLUME (MCV) 73.9 Low 83.0 - 101.0 fL METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM MEAN CORPUSCULAR HEMOGLOBIN (MCH) 23.4 Low 27.0 - 32.0 pg METHOD : CALCULATED PARAMETER BAN CORPUSCULAR HEMOGLOBIN (MCHC) 31.5 - 34.5 g/dL CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER 13.7 11.6 - 14.0 % METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM METHOD : DERIVED PARAMETER FROM PRO HISTOGRAM 14.4 MEAN PLATELET VOLUME (MPV) 12.7 High (6.8 - 10.9) fL METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM WBC DIFFERENTIAL COUNT VENTURE OF A SOLUTION (MICROSCOPY) W NEUTROPHILS 55 40 - 80 % METHOD : VCSN TECHNOLOGY/ MICROSCOPY SOLUTION (MICROSCOPY) W METHOD : VCSN TECHNOLOGY/ MICROSCOPY 11 High (2.0 - 10.0) % METHOD : VCSN TECHNOLOGY/ MICROSCOPY SOLUTION (MICROSCOPY) W SOLUTION (MICROSCOPY) W BASOPHILS 0 0 - 1 0 -	RBC AND PLATELET INDICES				
MEAN CORPUSCULAR VOLUME (MCV) METHOD: DERIVED PARAMETER FROM RBC HISTOGRAM MEAN CORPUSCULAR HEMOGLOBIN (MCH) METHOD: CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED PARAMETER RED CELL DISTRIBUTION WIDTH (RDW) 13.7 11.6 - 14.0 METHOD: DERIVED PARAMETER FROM RBC HISTOGRAM MENTZER INDEX 14.4 MEAN PLATELET VOLUME (MPV) METHOD: DERIVED PARAMETER FROM PLATELET HISTOGRAM WBC DIFFERENTIAL COUNT NEUTROPHILS 55 40 - 80 METHOD: VCSN TECHNOLOGY/ MICROSCOPY LYMPHOCYTES 33 20 - 40 METHOD: VCSN TECHNOLOGY/ MICROSCOPY MONOCYTES 11 High 2.0 - 10.0 METHOD: VCSN TECHNOLOGY/ MICROSCOPY EOSINOPHILS 1 1.0 - 6.0 METHOD: VCSN TECHNOLOGY/ MICROSCOPY BASOPHILS 0 0 1 - 1 METHOD: VCSN TECHNOLOGY/ MICROSCOPY BASOPHILS 0 0 0 - 1	HEMATOCRIT (PCV)	38.0	Low	40.0 - 50.0	%
METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM MEAN CORPUSCULAR HEMOGLOBIN (MCH) 23.4 Low 27.0 - 32.0 pg METHOD : CALCULATED PARAMETER 31.6 31.5 - 34.5 g/dL MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER 13.6 31.5 - 34.5 g/dL RED CELL DISTRIBUTION WIDTH (RDW) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM 13.7 11.6 - 14.0 % MENTZER INDEX 14.4 High 6.8 - 10.9 fL METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM WBC DIFFERENTIAL COUNT V NEUTROPHILS S 55 40 - 80 % METHOD : VCSN TECHNOLOGY/ MICROSCOPY V W W LYMPHOCYTES S 33 20 - 40 % METHOD : VCSN TECHNOLOGY/ MICROSCOPY T High 2.0 - 10.0 % METHOD : VCSN TECHNOLOGY/ MICROSCOPY T 1.0 - 6.0 % METHOD : VCSN TECHNOLOGY/ MICROSCOPY T 1.0 - 6.0 % BASOPHILS 0 0 - 1 %	METHOD: CALCULATED PARAMETER				
MEAN CORPUSCULAR HEMOGLOBIN (MCH) 23.4 Low 27.0 - 32.0 pg METHOD: CALCULATED PARAMETER 31.6 31.5 - 34.5 g/dL MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD: CALCULATED PARAMETER 31.6 31.5 - 34.5 g/dL RED CELL DISTRIBUTION WIDTH (RDW) 13.7 11.6 - 14.0 % METHOD: DERIVED PARAMETER FROM RBC HISTOGRAM 14.4 F F MEAN PLATELET VOLUME (MPV) 12.7 High 6.8 - 10.9 fL METHOD: DERIVED PARAMETER FROM PLATELET HISTOGRAM WBC DIFFERENTIAL COUNT 55 40 - 80 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY 33 20 - 40 % LYMPHOCYTES 33 20 - 40 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY 11 High 2.0 - 10.0 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY 1 1.0 - 6.0 % BASOPHILS 0 0 - 1 %	MEAN CORPUSCULAR VOLUME (MCV)	73.9	Low	83.0 - 101.0	fL
METHOD : CALCULATED PARAMETER MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER RED CELL DISTRIBUTION WIDTH (RDW) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM MENTZER INDEX MEAN PLATELET VOLUME (MPV) METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM MECHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM WBC DIFFERENTIAL COUNT NEUTROPHILS 55 40 - 80 METHOD : VCSN TECHNOLOGY/ MICROSCOPY LYMPHOCYTES 33 20 - 40 METHOD : VCSN TECHNOLOGY/ MICROSCOPY MONOCYTES METHOD : VCSN TECHNOLOGY/ MICROSCOPY MONOCYTES METHOD : VCSN TECHNOLOGY/ MICROSCOPY MONOCYTES METHOD : VCSN TECHNOLOGY/ MICROSCOPY BOSINOPHILS 1 1.0 - 6.0 METHOD : VCSN TECHNOLOGY/ MICROSCOPY BASOPHILS 0 0 - 1 %	METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM				
MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER RED CELL DISTRIBUTION WIDTH (RDW) 13.7 11.6 - 14.0 % METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM MENTZER INDEX 14.4 MEAN PLATELET VOLUME (MPV) 12.7 High 6.8 - 10.9 fL METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM WBC DIFFERENTIAL COUNT NEUTROPHILS 55 40 - 80 % METHOD : VCSN TECHNOLOGY/ MICROSCOPY LYMPHOCYTES 33 20 - 40 % METHOD : VCSN TECHNOLOGY/ MICROSCOPY MONOCYTES 11 High 2.0 - 10.0 % METHOD : VCSN TECHNOLOGY/ MICROSCOPY EOSINOPHILS 1 10 - 6.0 % METHOD : VCSN TECHNOLOGY/ MICROSCOPY BASOPHILS 0 0 0 - 1 %	MEAN CORPUSCULAR HEMOGLOBIN (MCH)	23.4	Low	27.0 - 32.0	pg
CONCENTRATION (MCHC) METHOD : CALCULATED PARAMETER RED CELL DISTRIBUTION WIDTH (RDW) METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM MENTZER INDEX 14.4 MEAN PLATELET VOLUME (MPV) METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM WBC DIFFERENTIAL COUNT NEUTROPHILS METHOD : VCSN TECHNOLOGY/ MICROSCOPY LYMPHOCYTES METHOD : VCSN TECHNOLOGY/ MICROSCOPY MONOCYTES METHOD : VCSN TECHNOLOGY/ MICROSCOPY METHOD : VCSN TECHNOLOGY/ MICROSCOPY EOSINOPHILS 1 10 - 6.0 METHOD : VCSN TECHNOLOGY/ MICROSCOPY BASOPHILS 0 0 - 1 %	METHOD: CALCULATED PARAMETER				
METHOD : CALCULATEÒ PARAMÉTER RED CELL DISTRIBUTION WIDTH (RDW) 13.7 11.6 - 14.0 % METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM MENTZER INDEX 14.4 MEAN PLATELET VOLUME (MPV) 12.7 High 6.8 - 10.9 fL METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM WBC DIFFERENTIAL COUNT NEUTROPHILS 55 40 - 80 % METHOD : VCSN TECHNOLOGY/ MICROSCOPY LYMPHOCYTES 33 20 - 40 % METHOD : VCSN TECHNOLOGY/ MICROSCOPY MONOCYTES 11 High 2.0 - 10.0 % METHOD : VCSN TECHNOLOGY/ MICROSCOPY EOSINOPHILS 1.0 - 6.0 % METHOD : VCSN TECHNOLOGY/ MICROSCOPY BASOPHILS 0 0 0 - 1 %	MEAN CORPUSCULAR HEMOGLOBIN	31.6		31.5 - 34.5	g/dL
METHOD : DERIVED PARAMETER FROM RBC HISTOGRAM MENTZER INDEX MEAN PLATELET VOLUME (MPV) METHOD : DERIVED PARAMETER FROM PLATELET HISTOGRAM WBC DIFFERENTIAL COUNT NEUTROPHILS METHOD : VCSN TECHNOLOGY/ MICROSCOPY LYMPHOCYTES METHOD : VCSN TECHNOLOGY/ MICROSCOPY MONOCYTES METHOD : VCSN TECHNOLOGY/ MICROSCOPY EOSINOPHILS METHOD : VCSN TECHNOLOGY/ MICROSCOPY MONOCYTES METHOD : VCSN TECHNOLOGY/ MICROSCOPY BASOPHILS 0 0 0 0 0 0 0 0 0 0 0 0 0					
METHOD: DERIVED PARAMETER FROM RBC HISTOGRAM MENTZER INDEX MEAN PLATELET VOLUME (MPV) METHOD: DERIVED PARAMETER FROM PLATELET HISTOGRAM WBC DIFFERENTIAL COUNT NEUTROPHILS METHOD: VCSN TECHNOLOGY/ MICROSCOPY LYMPHOCYTES METHOD: VCSN TECHNOLOGY/ MICROSCOPY MONOCYTES METHOD: VCSN TECHNOLOGY/ MICROSCOPY EOSINOPHILS METHOD: VCSN TECHNOLOGY/ MICROSCOPY BASOPHILS 0 0 0 0 0 0 0 0 0 0 0 0 0	RED CELL DISTRIBUTION WIDTH (RDW)	13.7		11.6 - 14.0	%
MEAN PLATELET VOLUME (MPV) METHOD: DERIVED PARAMETER FROM PLATELET HISTOGRAM WBC DIFFERENTIAL COUNT NEUTROPHILS S5 40 - 80 METHOD: VCSN TECHNOLOGY/ MICROSCOPY LYMPHOCYTES 33 20 - 40 METHOD: VCSN TECHNOLOGY/ MICROSCOPY MONOCYTES METHOD: VCSN TECHNOLOGY/ MICROSCOPY EOSINOPHILS 11 High 2.0 - 10.0 METHOD: VCSN TECHNOLOGY/ MICROSCOPY EOSINOPHILS 0 0 - 1 %					
METHOD: DERIVED PARAMETER FROM PLATELET HISTOGRAM WBC DIFFERENTIAL COUNT NEUTROPHILS 55 40 - 80 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY LYMPHOCYTES 33 20 - 40 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY MONOCYTES 11 High 2.0 - 10.0 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY EOSINOPHILS 1.0 - 6.0 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY BASOPHILS 0 0 - 1 %	MENTZER INDEX	14.4			
METHOD: DERIVED PARAMETER FROM PLATELET HISTOGRAM WBC DIFFERENTIAL COUNT NEUTROPHILS 55 40 - 80 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY LYMPHOCYTES 33 20 - 40 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY MONOCYTES 11 High 2.0 - 10.0 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY EOSINOPHILS 1.0 - 6.0 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY BASOPHILS 0 0 - 1 %	MEAN PLATELET VOLUME (MPV)	12.7	High	6.8 - 10.9	fl
NEUTROPHILS 55 40 - 80 %	` ,	,	_	0.0 20.5	
METHOD: VCSN TECHNOLOGY/ MICROSCOPY LYMPHOCYTES 33 20 - 40 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY MONOCYTES 11 High 2.0 - 10.0 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY EOSINOPHILS 1.0 - 6.0 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY BASOPHILS 0 0 0 - 1 %	WBC DIFFERENTIAL COUNT				
METHOD: VCSN TECHNOLOGY/ MICROSCOPY LYMPHOCYTES 33 20 - 40 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY MONOCYTES 11 High 2.0 - 10.0 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY EOSINOPHILS 1.0 - 6.0 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY BASOPHILS 0 0 0 - 1 %	NEUTROPHILS	55		40 - 80	%
LYMPHOCYTES 33 20 - 40 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY MONOCYTES 11 High 2.0 - 10.0 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY EOSINOPHILS 1.0 - 6.0 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY BASOPHILS 0 0 - 1 %					
METHOD: VCSN TECHNOLOGY/ MICROSCOPY MONOCYTES 11 High 2.0 - 10.0 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY EOSINOPHILS 1 1.0 - 6.0 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY BASOPHILS 0 0 - 1 %		33		20 - 40	%
MONOCYTES 11 High 2.0 - 10.0 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY EOSINOPHILS 1 1.0 - 6.0 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY BASOPHILS 0 0 - 1 %					
EOSINOPHILS 1 1.0 - 6.0 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY BASOPHILS 0 0 - 1 %	MONOCYTES	11	High	2.0 - 10.0	%
EOSINOPHILS 1 1.0 - 6.0 % METHOD: VCSN TECHNOLOGY/ MICROSCOPY BASOPHILS 0 0 - 1 %			_		-
METHOD: VCSN TECHNOLOGY/ MICROSCOPY BASOPHILS 0 0 - 1 %	EOSINOPHILS	1		1.0 - 6.0	%
	BASOPHILS	0		0 - 1	%
	METHOD : VCSN TECHNOLOGY/ MICROSCOPY				











CODE: C000138400

NAME AND ADDRESS:

SINGRAY KORAH

B 502 MANASMOTI APT GOREGAON East

Mumbai 400097 MAHARASHTRA

Cert. No. MC-2010

SRL Ltd

PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL

ESTATE, S.V. ROAD, GOREGAON (W)

Mumbai, 400062 MAHARASHTRA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956

PATIENT ID: **PATIENT NAME: SINGRAY KORAH** SINGM0808782

ACCESSION NO: 0002VK055472 AGE: 44 Years SEX: Male ABHA NO:

RECEIVED: 26/11/2022 08:54:36 DRAWN: 26/11/2022 08:52:50 REPORTED: 29/11/2022 15:05:40

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results		Biological Reference	e Interval Units
ABSOLUTE NEUTROPHIL COUNT METHOD: CALCULATED PARAMETER	1.87	Low	2.0 - 7.0	thou/µL
ABSOLUTE LYMPHOCYTE COUNT METHOD : CALCULATED PARAMETER	1.12		1.0 - 3.0	thou/μL
ABSOLUTE MONOCYTE COUNT METHOD: CALCULATED PARAMETER	0.37		0.2 - 1.0	thou/μL
ABSOLUTE EOSINOPHIL COUNT METHOD: CALCULATED PARAMETER	0.03		0.02 - 0.50	thou/μL
ABSOLUTE BASOPHIL COUNT METHOD: CALCULATED PARAMETER	0	Low	0.02 - 0.10	thou/μL
NEUTROPHIL LYMPHOCYTE RATIO (NLR) METHOD: CALCULATED	1.7			
MORPHOLOGY				
RBC METHOD: MICROSCOPIC EXAMINATION	Mild anisopoikilo	cytosis. Mi	crocytic hypochromic v	vith ovalocytes.
WBC METHOD: MICROSCOPIC EXAMINATION	Leucopenia is pr	esent.		
PLATELETS	Reduced in smea	ar. Giant p	atelets are seen.	

METHOD: ELECTRONIC IMPEDENCE & MICROSCOPY

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD

E.S.R 0 - 14 mm at 1 hr

METHOD: AUTOMATED (PHOTOMETRICAL CAPILLARY STOPPED FLOW KINETIC ANALYSIS)

GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD

HBA1C Non-diabetic Adult < 5.7 % 5.1 Pre-diabetes 5.7 - 6.4 Diabetes diagnosis: > or = 6.5

Therapeutic goals: < 7.0 Action suggested: > 8.0 (ADA Guideline 2021)

METHOD: ION-EXCHANGE HPLC

ESTIMATED AVERAGE GLUCOSE(EAG) 99.7 < 116.0 mg/dL

METHOD: CALCULATED PARAMETER

GLUCOSE FASTING, FLUORIDE PLASMA



Page 2 Of 18 Scan to View Report







CODE: C000138400

NAME AND ADDRESS:

SINGRAY KORAH

B 502 MANASMOTI APT GOREGAON East

Mumbai 400097 MAHARASHTRA

Cert. No. MC-2010

SRL Ltd

PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL

ESTATE, S.V. ROAD, GOREGAON (W)

Mumbai, 400062 MAHARASHTRA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956

PATIENT NAME: SINGRAY KORAH PATIENT ID: SINGM0808782

ACCESSION NO: **0002VK055472** AGE: 44 Years SEX: Male ABHA NO:

DRAWN: 26/11/2022 08:52:50 RECEIVED: 26/11/2022 08:54:36 REPORTED: 29/11/2022 15:05:40

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status	<u>Final</u>	Results		Biological Reference Interva	l Units
FBS (FASTING BLOOD	ŕ	87		Normal <100 Impaired fasting glucose:100 to 125 Diabetes mellitus: > = 126 (on more than 1 occassion) (ADA guidelines 2021)	mg/dL)
METHOD : SPECTROPHOTOM					
GLUCOSE, POST-PRA	•				
PPBS(POST PRANDIAL	BLOOD SUGAR)	84		Normal <140 Impaired glucose tolerance:140 to 199 Diabetes mellitus : > = 200 (on more than 1 occassion) ADA guideline 2021	mg/dL
METHOD : SPECTROPHOTOM	IETRY HEXOKINASE				
LIPID PROFILE, SER	UM				
CHOLESTEROL, TOTAL		167		Desirable : < 200 Borderline : 200 - 239 High : > / = 240	mg/dL
METHOD : SPECTROPHOTOM	METRY, ENZYMATIC COLORIM	ETRIC - CHOLETSEROL OXIDASE, E	STERASE, PERO	· .	
TRIGLYCERIDES		89		Normal: < 150 Borderline high: 150 - 199 High: 200 - 499 Very High: >/= 500	mg/dL
METHOD : SPECTROPHOTOM	TETRY, ENZYMATIC ENDPOIN	T WITH GLYCEROL BLANK		, , ,	
HDL CHOLESTEROL		34	Low	At Risk: < 40 Desirable: > or = 60	mg/dL
	IETRY, HOMOGENEOUS DIRE	CT ENZYMATIC COLORIMETRIC	Wigh	Ontinend of 100	
CHOLESTEROL LDL		115	nigii	Optimal: < 100 Near optimal/above optimal: 10 129 Borderline high: 130-159 High: 160-189 Very high: = 190	mg/dL 00-
METHOD : CALCULATED PAR	RAMETER			very mgm . – 190	
NON HDL CHOLESTER	DL	133	High	Desirable : < 130 Above Desirable : 130 -159 Borderline High : 160 - 189 High : 190 - 219 Very high : > / = 220	mg/dL



METHOD: CALCULATED PARAMETER

Scan to View Report

Page 3 Of 18







CODE: C000138400

NAME AND ADDRESS:

SINGRAY KORAH B 502 MANASMOTI APT GOREGAON East

Mumbai 400097 MAHARASHTRA Cert. No. MC-2010

SRL Ltd

PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL

ESTATE, S.V. ROAD, GOREGAON (W)

Mumbai, 400062 MAHARASHTRA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956

PATIENT NAME: SINGRAY KORAH PATIENT ID: SINGM0808782

ACCESSION NO: 0002VK055472 AGE: 44 Years SEX: Male ABHA NO:

DRAWN: 26/11/2022 08:52:50 RECEIVED: 26/11/2022 08:54:36 REPORTED: 29/11/2022 15:05:40

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status	<u>Final</u>	Results		Biological Reference Interva	l Units
CHOL/HDL RATIO		4.9	High	Low Risk: 3.3 - 4.4 Average Risk: 4.5 - 7.0 Moderate Risk: 7.1 - 11.0 High Risk: > 11.0	
METHOD : CALCULATED PAR LDL/HDL RATIO	AMETER	3.3	High	Desirable/Low Risk: 0.5 - 3.0 Borderline/Moderate Risk: 3.1	
				6.0 High Risk : > 6.0	-
METHOD : CALCULATED PAR	AMETER				
VERY LOW DENSITY LI	POPROTEIN	18.0		< or = 30.0	mg/dL
METHOD : CALCULATED PAR	AMETER				
LIVER FUNCTION PR	OFILE, SERUM				
BILIRUBIN, TOTAL		0.64		Upto 1.2	mg/dL
METHOD: SPECTROPHOTOM	ETRY, COLORIMETRIC -DIAZO METHOD				
BILIRUBIN, DIRECT		0.26	High	0.0 - 0.2	mg/dL
METHOD: SPECTROPHOTOM	ETRY, JENDRASSIK & GROFF - DIAZOTIZ	ATION			
BILIRUBIN, INDIRECT		0.38		0.1 - 1.0	mg/dL
METHOD : CALCULATED PAR	AMETER				
TOTAL PROTEIN		6.8		6.0 - 8.0	g/dL
METHOD: SPECTROPHOTOM	ETRY, COLORIMETRIC -BIURET, REAGEN	T BLANK, SERUM BLANK			
ALBUMIN		4.7		3.97 - 4.94	g/dL
METHOD: SPECTROPHOTOM	ETRY, BROMOCRESOL GREEN(BCG) - DY	E BINDING			
GLOBULIN		2.1		2.0 - 3.5	g/dL
METHOD : CALCULATED PAR	AMETER				
ALBUMIN/GLOBULIN R	ΑΠΟ	2.2	High	1.0 - 2.1	RATIO
METHOD : CALCULATED PAR					
	NSFERASE (AST/SGOT)	35		Upto 40	U/L
	ETRY, WITHOUT PYRIDOXAL PHOSPHATE	` ,			
ALANINE AMINOTRANS	, ,	46	High	Upto 41	U/L
	IETRY, WITHOUT PYRIDOXAL PHOSPHATE	` ,			
ALKALINE PHOSPHATAS		112		40 - 129	U/L
	IETRY, PNPP, AMP BUFFER - IFCC				
GAMMA GLUTAMYL TRA	` ,	22		< 60	U/L
	IETRY, ENZYMATIC COLORIMETRIC - G-G		ILIDE - II		
LACTATE DEHYDROGEN		206		< 232	U/L
METHOD: SPECTROPHOTOM	IETRY, LACTATE TO PYRUVATE - UV-IFCC				











CODE: C000138400

NAME AND ADDRESS:

SINGRAY KORAH B 502 MANASMOTI APT GOREGAON East

Mumbai 400097 MAHARASHTRA Cert. No. MC-2010

SRL Ltd

PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL

ESTATE, S.V. ROAD, GOREGAON (W)

Mumbai, 400062 MAHARASHTRA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956

PATIENT NAME: SINGRAY KORAH PATIENT ID: SINGM0808782

ACCESSION NO: 0002VK055472 AGE: 44 Years SEX: Male ABHA NO:

DRAWN: 26/11/2022 08:52:50 RECEIVED: 26/11/2022 08:54:36 REPORTED: 29/11/2022 15:05:40

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status	<u>Final</u>	Results	Biological Reference	Interval Units
BLOOD UREA NITRO	GEN (BUN), SERI	JM		
BLOOD UREA NITROGE	ΞN	8	6 - 20	mg/dL
METHOD: SPECTROPHOTOM	TETRY, UREASE -COLORIM	1ETRIC		
CREATININE, SERUM	1			
CREATININE		0.92	0.90 - 1.30	mg/dL
METHOD: SPECTROPHOTOM	METRY, JAFFE'S ALKALINE	PICRATE KINETIC - RATE BLANKED - IFCC-	IDMS STANDARIZED	
BUN/CREAT RATIO				
BUN/CREAT RATIO		8.60	8 - 15	
METHOD : CALCULATED PAR	RAMETER			
URIC ACID, SERUM				
URIC ACID		6.1	3.4 - 7.0	mg/dL
METHOD : SPECTROPHOTOM	METRY, ENZYMATIC COLOR	RIMETRIC- URICASE		
TOTAL PROTEIN, SE	RUM			
TOTAL PROTEIN		6.8	6.0 - 8.0	g/dL
METHOD : SPECTROPHOTOM	METRY, COLORIMETRIC -B	IURET, REAGENT BLANK, SERUM BLANK		
ALBUMIN, SERUM				
ALBUMIN		4.7	3.97 - 4.94	g/dL
METHOD : SPECTROPHOTOM	METRY, BROMOCRESOL GF	REEN(BCG) - DYE BINDING		
GLOBULIN				
GLOBULIN		2.1	2.0 - 3.5	g/dL
METHOD : CALCULATED PAR	RAMETER			
ELECTROLYTES (NA/	/K/CL), SERUM			
SODIUM, SERUM		142	136 - 145	mmol/L
METHOD : ISE INDIRECT				
POTASSIUM, SERUM		4.10	3.5 - 5.1	mmol/L
METHOD : ISE INDIRECT				
CHLORIDE, SERUM		103	98 - 106	mmol/L
METHOD : ISE INDIRECT				



Page 5 Of 18







CODE: C000138400

NAME AND ADDRESS:

SINGRAY KORAH B 502 MANASMOTI APT GOREGAON East

Mumbai 400097 MAHARASHTRA

Cert. No. MC-2010

SRL Ltd

PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL

ESTATE, S.V. ROAD, GOREGAON (W)

Mumbai, 400062 MAHARASHTRA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956

PATIENT NAME: SINGRAY KORAH PATIENT ID: SINGM0808782

ACCESSION NO: **0002VK055472** AGE: 44 Years SEX: Male ABHA NO:

DRAWN: 26/11/2022 08:52:50 RECEIVED: 26/11/2022 08:54:36 29/11/2022 15:05:40 REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status **Final** Results **Biological Reference Interval Units**

Interpretation(s)

Sodium	Potassium	Chloride
Decreased in:CCF, cirrhosis, vomiting, diarrhea, excessive sweating, salt-losing nephropathy, adrenal insufficiency, nephrotic syndrome, water intoxication, SIADH. Drugs: thiazides, diuretics, ACE inhibitors, chlorpropamide, carbamazepine, anti depressants (SSRI), antipsychotics.	Decreased in: Low potassium intake, prolonged vomiting or diarrhea, RTA types I and II, hyperaldosteronism, Cushing's syndrome, osmotic diuresis (e.g., hyperglycemia), alkalosis, familial periodic paralysis, trauma (transient). Drugs: Adrenergic agents, diuretics.	Decreased in: Vomiting, diarrhea, renal failure combined with salt deprivation, over-treatment with diuretics, chronic respiratory acidosis, diabetic ketoacidosis, excessive sweating, SIADH, salt-losing nephropathy, porphyria, expansion of extracellular fluid volume, adrenalinsufficiency, hyperaldosteronism, metabolic alkalosis. Drugs: chronic laxative, corticosteroids, diuretics.
Increased in: Dehydration (excessivesweating, severe vomiting or diarrhea),diabetes mellitus, diabetesinsipidus, hyperaldosteronism, inadequate water intake. Drugs: steroids, licorice,oral contraceptives.	Increased in: Massive hemolysis, severe tissue damage, rhabdomyolysis, acidosis, dehydration, renal failure, Addison's disease, RTA type IV, hyperkalemic familial periodic paralysis. Drugs: potassium salts, potassium- sparing diuretics, NSAIDs, beta-blockers, ACE inhibitors, highdose trimethoprim-sulfamethoxazole.	Increased in: Renal failure, nephrotic syndrome, RTA, dehydration, overtreatment with saline, hyperparathyroidism, diabetes insipidus, metabolic acidosis from diarrhea (Loss of HCO3-), respiratory alkalosis, hyperadrenocorticism. Drugs: acetazolamide, androgens, hydrochlorothiazide, salicylates.
Interferences: Severe lipemia or hyperproteinemi, if sodium analysis involves a dilution step can cause spurious results. The serum sodium falls about 1.6 mEq/L for each 100 mg/dL increase in blood glucose.	Interferences: Hemolysis of sample, delayed separation of serum, prolonged fist clenching during blood drawing, and prolonged tourniquet placement. Very high WBC/PLT counts may cause spurious. Plasma potassium levels are normal.	Interferences:Test is helpful in assessing normal and increased anion gap metabolic acidosis and in distinguishing hypercalcemia due to hyperparathyroidism (high serum chloride) from that due to malignancy (Normal serum chloride)

PHYSICAL EXAMINATION, URINE

CHEMICAL EXAMINATION, URINE	
APPEARANCE	CLEAR
COLOR	PALE YELLOW

PH	6.5		5.00 - 7.50
SPECIFIC GRAVITY	1.005	Low	1.010 - 1.030
PROTEIN	NOT DETECTED		NOT DETECTED
GLUCOSE	NOT DETECTED		NOT DETECTED
KETONES	NOT DETECTED		NOT DETECTED
BLOOD	NOT DETECTED		NOT DETECTED
BILIRUBIN	NOT DETECTED		NOT DETECTED
UROBILINOGEN	NOT DETECTED		
NITRITE	NOT DETECTED		NOT DETECTED



Page 6 Of 18 Scan to View Report







CODE: C000138400

NAME AND ADDRESS:

SINGRAY KORAH B 502 MANASMOTI APT GOREGAON East

Mumbai 400097 MAHARASHTRA

Cert. No. MC-2010

SRL Ltd PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL

ESTATE, S.V. ROAD, GOREGAON (W)

Mumbai, 400062 MAHARASHTRA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956

PATIENT NAME: SINGRAY KORAH PATIENT ID: SINGM0808782

ACCESSION NO : **0002VK055472** AGE: 44 Years SEX: Male ABHA NO:

DRAWN: 26/11/2022 08:52:50 RECEIVED: 26/11/2022 08:54:36 29/11/2022 15:05:40 REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u>	Results	Biological Reference	Reference Interval Units	
LEUKOCYTE ESTERASE	NOT DETECTED	NOT DETECTED		
MICROSCOPIC EXAMINATION, URINE				
RED BLOOD CELLS	NOT DETECTED	NOT DETECTED	/HPF	
PUS CELL (WBC'S)	0-1	0-5	/HPF	
EPITHELIAL CELLS	0-1	0-5	/HPF	
CASTS	NOT DETECTED			
CRYSTALS	NOT DETECTED			
BACTERIA	NOT DETECTED	NOT DETECTED		
YEAST	NOT DETECTED	NOT DETECTED		
CRYSTALS BACTERIA	NOT DETECTED NOT DETECTED NOT DETECTED			

METHOD: URINE ROUTINE & MICROSCOPY EXAMINATION BY INTEGRATED AUTOMATED SYSTEM

Comments

NOTE: KINDLY EXERT CAUTION DURING INTERPRETATION OF FINDINGS REPORTED IN URINALYSIS WHERE IN THE SAMPLE IS MORE THAN TWO HOURS OLD.











CODE: C000138400

NAME AND ADDRESS:

SINGRAY KORAH B 502 MANASMOTI APT GOREGAON East

Mumbai 400097 MAHARASHTRA Cert. No. MC-2010

SRL Ltd

PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL

ESTATE, S.V. ROAD, GOREGAON (W)

Mumbai, 400062 MAHARASHTRA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956

PATIENT NAME: SINGRAY KORAH PATIENT ID: SINGM0808782

ACCESSION NO: 0002VK055472 AGE: 44 Years SEX: Male ABHA NO:

DRAWN: 26/11/2022 08:52:50 RECEIVED: 26/11/2022 08:54:36 REPORTED: 29/11/2022 15:05:40

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status <u>Final</u> Results Biological Reference Interval Units

Interpretation(s)

The following table describes the probable conditions, in which the analytes are present in urine

Presence of	Conditions
Proteins	Inflammation or immune illnesses
Pus (White Blood Cells)	Urinary tract infection, urinary tract or kidney stone, tumors or any kind
	of kidney impairment
Glucose	Diabetes or kidney disease
Ketones	Diabetic ketoacidosis (DKA), starvation or thirst
Urobilinogen	Liver disease such as hepatitis or cirrhosis
Blood	Renal or genital disorders/trauma
Bilirubin	Liver disease
Erythrocytes	Urological diseases (e.g. kidney and bladder cancer, urolithiasis), urinary
	tract infection and glomerular diseases
Leukocytes	Urinary tract infection, glomerulonephritis, interstitial nephritis either
	acute or chronic, polycystic kidney disease, urolithiasis, contamination by
	genital secretions
Epithelial cells	Urolithiasis, bladder carcinoma or hydronephrosis, ureteric stents or
	bladder catheters for prolonged periods of time
Granular Casts	Low intratubular pH, high urine osmolality and sodium concentration, interaction with Bence-Jones protein
Hyaline casts	Physical stress, fever, dehydration, acute congestive heart failure, renal
5	diseases
Calcium oxalate	Metabolic stone disease, primary or secondary hyperoxaluria, intravenous
	infusion of large doses of vitamin C, the use of vasodilator naftidrofuryl
	oxalate or the gastrointestinal lipase inhibitor orlistat, ingestion of
	ethylene glycol or of star fruit (Averrhoa carambola) or its juice
Uric acid	arthritis
Bacteria	Urinary infectionwhen present in significant numbers & with pus cells.
Trichomonas vaginalis	Vaginitis, cervicitis or salpingitis

THYROID PANEL, SERUM

T3 **77.7 Low** 80.0 - 200.0 ng/dL

METHOD: COMPETITIVE ELECTROCHEMILUMINESCENCE IMMUNOASSAY

T4 **4.03 Low** 5.10 - 14.10 μg/dL

 ${\tt METHOD}: {\tt COMPETITIVE} \ {\tt ELECTROCHEMILUMINESCENCE} \ {\tt IMMUNOASSAY}$

TSH (ULTRASENSITIVE) **10.200 High** 0.270 - 4.200 μIU/mL

METHOD: SANDWICH ELECTROCHEMILUMINESCENCE IMMUNOASSAY











CODE: C000138400

NAME AND ADDRESS:

SINGRAY KORAH B 502 MANASMOTI APT GOREGAON East

Mumbai 400097 MAHARASHTRA

Cert. No. MC-2010

SRL Ltd

PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W)

Mumbai, 400062 MAHARASHTRA, INDIA

Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956

PATIENT NAME: SINGRAY KORAH PATIENT ID: SINGM0808782

ACCESSION NO: 0002VK055472 AGE: 44 Years SEX: Male ABHA NO:

DRAWN: 26/11/2022 08:52:50 RECEIVED: 26/11/2022 08:54:36 REPORTED: 29/11/2022 15:05:40

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status **Final** Results Biological Reference Interval Units

Interpretation(s)

Triiodothyronine T3, Thyroxine T4, and Thyroid Stimulating Hormone TSH are thyroid hormones which affect almost every physiological process in the body, including growth, development, metabolism, body temperature, and heart rate.

Production of T3 and its prohormone thyroxine (T4) is activated by thyroid-stimulating hormone (TSH), which is released from the pituitary gland. Elevated concentrations of T3, and T4 in the blood inhibit the production of TSH.

Excessive secretion of thyroxine in the body is hyperthyroidism, and deficient secretion is called hypothyroidism.

In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hyporthyroidism, TSH levels are low. Below mentioned are the guidelines for Pregnancy related reference ranges for Total T4, TSH & Total T3. Measurement of the serum TT3 level is a more sensitive test for the diagnosis of hyperthyroidism, and measurement of TT4 is more useful in the diagnosis of hypothyroidism. Most of the thyroid hormone in blood is bound to transport proteins. Only a very small fraction of the circulating hormone is free and biologically active. It is advisable to detect Free T3, Free T4 along with TSH, instead of testing for albumin bound Total T3, Total T4.

Sr. No.	TSH	Total T4	FT4	Total T3	Possible Conditions
1	High	Low	Low	Low	(1) Primary Hypothyroidism (2) Chronic autoimmune Thyroiditis (3)
		A 2 4 4			Post Thyroidectomy (4) Post Radio-Iodine treatment
2	High	Normal	Normal	Normal	(1)Subclinical Hypothyroidism (2) Patient with insufficient thyroid
					hormone replacement therapy (3) In cases of Autoimmune/Hashimoto
					thyroiditis (4). Isolated increase in TSH levels can be due to Subclinical
					inflammation, drugs like amphetamines, Iodine containing drug and
					dopamine antagonist e.g. domperidone and other physiological reasons.
3	Normal/Low	Low	Low	Low	(1) Secondary and Tertiary Hypothyroidism
4	Low	High	High	High	(1) Primary Hyperthyroidism (Graves Disease) (2) Multinodular Goitre
	3-				(3)Toxic Nodular Goitre (4) Thyroiditis (5) Over treatment of thyroid
					hormone (6) Drug effect e.g. Glucocorticoids, dopamine, T4
					replacement therapy (7) First trimester of Pregnancy
5	Low	Normal	Normal	Normal	(1) Subclinical Hyperthyroidism
6	High	High	High	High	(1) TSH secreting pituitary adenoma (2) TRH secreting tumor
7	Low	Low	Low	Low	(1) Central Hypothyroidism (2) Euthyroid sick syndrome (3) Recent
					treatment for Hyperthyroidism
8	Normal/Low	Normal	Normal	High	(1) T3 thyrotoxicosis (2) Non-Thyroidal illness
9	Low	High	High	Normal	(1) T4 Ingestion (2) Thyroiditis (3) Interfering Anti TPO antibodies

REF: 1. TIETZ Fundamentals of Clinical chemistry 2. Guidlines of the American Thyroid association during pregnancy and Postpartum, 2011. NOTE: It is advisable to detect Free T3, FreeT4 along with TSH, instead of testing for albumin bound Total T3, Total T4.TSH is not affected by variation in thyroid - binding protein. TSH has a diurnal rhythm, with peaks at 2:00 - 4:00 a.m. And troughs at 5:00 - 6:00 p.m. With ultradian variations.

STOOL: OVA & PARASITE

REMARK

TEST CANCELLED AS SPECIMEN NOT RECEIVED











CODE: C000138400

NAME AND ADDRESS:

SINGRAY KORAH B 502 MANASMOTI APT GOREGAON East

Mumbai 400097 MAHARASHTRA

Cert. No. MC-2010

SRL Ltd

PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL

ESTATE, S.V. ROAD, GOREGAON (W)

Mumbai, 400062 MAHARASHTRA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956

PATIENT NAME: SINGRAY KORAH PATIENT ID: SINGM0808782

ACCESSION NO: 0002VK055472 44 Years SEX: Male ABHA NO:

DRAWN: 26/11/2022 08:52:50 RECEIVED: 26/11/2022 08:54:36 REPORTED: 29/11/2022 15:05:40

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status **Final** Results Biological Reference Interval Units

Interpretation(s)

Stool routine analysis is only a screening test for disorders of gastrointentestinal tract like infection, malabsorption, etc. The following table describes the probable conditions, in which the analytes are present in stool.

PRESENCE OF	CONDITION
Pus cells	Pus in the stool is an indication of infection
Red Blood cells	Parasitic or bacterial infection or an inflammatory bowel condition such as ulcerative colitis
Parasites	Infection of the digestive system. Stool examination for ova and parasite detects presence of parasitic infestation of gastrointestinal tract. Various forms of parasite that can be detected include cyst, trophozoite and larvae. One negative result does not rule out the possibility of parasitic infestation. Intermittent shedding of parasites warrants examinations of multiple specimens tested on consecutive days. Stool specimens for parasitic examination should be collected before initiation of antidiarrheal therapy or antiparasitic therapy. This test does not detect presence of opportunistic parasites like Cyclospora, Cryptosporidia and Isospora species. Examination of Ova and Parasite has been carried out by direct and concentration techniques.
Mucus	Mucus is a protective layer that lubricates, protects& reduces damage due to bacteria or viruses.
Charcot-Leyden crystal	Parasitic diseases.
Ova & cyst	Ova & cyst indicate parasitic infestation of intestine.
Frank blood	Bleeding in the rectum or colon.
Occult blood	Occult blood indicates upper GI bleeding.
Macrophages	Macrophages in stool are an indication of infection as they are protective cells.
Epithelial cells	Epithelial cells that normally line the body surface and internal organs show up in stool when there is inflammation or infection.
Fat	Increased fat in stool maybe seen in conditions like diarrhoea or malabsorption.
pH	Normal stool pH is slightly acidic to neutral. Breast-fed babies generally have an acidic stool.

ADDITIONAL STOOL TESTS:

- Stool Culture:- This test is done to find cause of GI infection, make decision about best treatment for GI infection & to find out if 1. treatment for GI infection worked.
- Fecal Calprotectin: It is a marker of intestinal inflammation. This test is done to differentiate Inflammatory Bowel Disease (IBD) 2. from Irritable Bowel Syndrome (IBS).
- Fecal Occult Blood Test(FOBT): This test is done to screen for colon cancer & to evaluate possible cause of unexplained anaemia. 3.
- 4. Clostridium Difficile Toxin Assay: This test is strongly recommended in healthcare associated bloody or waterydiarrhoea, due to overuse of broad spectrum antibiotics which alter the normal GI flora.
- 5. Biofire (Film Array) GI PANEL: In patients of Diarrhoea, Dysentry, Rice watery Stool, FDA approved, Biofire Film Array Test,(Real Time Multiplex PCR) is strongly recommended as it identifies organisms, bacteria, fungi, virus, parasite and other





Page 10 Of 18







CODE: C000138400

NAME AND ADDRESS:

B 502 MANASMOTI APT GOREGAON East

Mumbai 400097 MAHARASHTRA

SINGRAY KORAH

Cert. No. MC-2010

SRL Ltd

PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL

ESTATE, S.V. ROAD, GOREGAON (W)

Mumbai, 400062 MAHARASHTRA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956

PATIENT NAME: SINGRAY KORAH PATIENT ID: SINGM0808782

ACCESSION NO: 0002VK055472 AGE: 44 Years SEX: Male ABHA NO:

DRAWN: 26/11/2022 08:52:50 RECEIVED: 26/11/2022 08:54:36 REPORTED: 29/11/2022 15:05:40

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status **Final** Results Biological Reference Interval Units

opportunistic pathogens, Vibrio cholera infections only in 3 hours. Sensitivity 96% & Specificity 99%.

Rota Virus Immunoassay: This test is recommended in severe gastroenteritis in infants & children associated with watery diarrhoea, vomitting& abdominal cramps. Adults are also affected. It is highly contagious in nature.

ABO GROUP & RH TYPE, EDTA WHOLE BLOOD

0 ABO GROUP

METHOD: HAEMAGGLUTINATION (AUTOMATED)

RH TYPE **POSITIVE**

METHOD: HAEMAGGLUTINATION (AUTOMATED)

* XRAY-CHEST

IMPRESSION NO ABNORMALITY DETECTED

TMT OR ECHO

TMT OR ECHO **NORMAL**

* ECG

ECG ST AND TABNORMALITY INFERIOR OR DAMAGE

NORMAL WITH EARLY REPOLARIZATION

* MEDICAL HISTORY

RELEVANT PRESENT HISTORY **NOT SIGNIFICANT**

RELEVANT PAST HISTORY COVID 19 INFECTION 2021

RELEVANT PERSONAL HISTORY ALCOHOL- OCC RELEVANT FAMILY HISTORY **NOT SIGNIFICANT** HISTORY OF MEDICATIONS NOT SIGNIFICANT

* ANTHROPOMETRIC DATA & BMI

HEIGHT IN METERS 1.67 mts WEIGHT IN KGS. 71.6 Kgs

BMI BMI & Weight Status as follows: kg/sqmts 26

Below 18.5: Underweight 18.5 - 24.9: Normal 25.0 - 29.9: Overweight 30.0 and Above: Obese

* GENERAL EXAMINATION

MENTAL / EMOTIONAL STATE **NORMAL** PHYSICAL ATTITUDE **NORMAL** GENERAL APPEARANCE / NUTRITIONAL STATUS **OVERWEIGHT BUILT / SKELETAL FRAMEWORK AVERAGE** NORMAL FACIAL APPEARANCE





Page 11 Of 18







CODE: C000138400

NAME AND ADDRESS:

SINGRAY KORAH B 502 MANASMOTI APT GOREGAON East

Mumbai 400097 MAHARASHTRA

Cert. No. MC-2010

SRL Ltd

PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL

ESTATE, S.V. ROAD, GOREGAON (W)

Mumbai, 400062 MAHARASHTRA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956

PATIENT NAME: SINGRAY KORAH PATIENT ID: SINGM0808782

ACCESSION NO: 0002VK055472 AGE: 44 Years SEX: Male ABHA NO:

DRAWN: 26/11/2022 08:52:50 RECEIVED: 26/11/2022 08:54:36 REPORTED: 29/11/2022 15:05:40

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status **Final** Results Biological Reference Interval Units

SKIN **NORMAL** UPPER LIMB **NORMAL** LOWER LIMB **NORMAL NECK NORMAL**

NECK LYMPHATICS / SALIVARY GLANDS NOT ENLARGED OR TENDER

THYROID GLAND **NOT ENLARGED**

CAROTID PULSATION **NORMAL TEMPERATURE NORMAL**

72/MIN REGULAR, ALL PERIPHERAL PULSES WELL FELT, NO CAROTID **PULSE**

BRUIT

RESPIRATORY RATE **NORMAL**

* CARDIOVASCULAR SYSTEM

120/76 MM HG BP mm/Hg

(SUPINE) **NORMAL NORMAL**

APEX BEAT

HEART SOUNDS S1, S2 HEARD NORMALLY

ABSENT **MURMURS**

* RESPIRATORY SYSTEM

SIZE AND SHAPE OF CHEST **NORMAL** MOVEMENTS OF CHEST **SYMMETRICAL BREATH SOUNDS INTENSITY NORMAL**

BREATH SOUNDS QUALITY VESICULAR (NORMAL)

ADDED SOUNDS **ABSENT**

* PER ABDOMEN

PERICARDIUM

APPEARANCE NORMAL VENOUS PROMINENCE **ABSENT**

NOT PALPABLE LIVER NOT PALPABLE SPLEEN HERNIA ABSENT

* CENTRAL NERVOUS SYSTEM

HIGHER FUNCTIONS **NORMAL** CRANIAL NERVES **NORMAL**











CODE: C000138400

NAME AND ADDRESS:

SINGRAY KORAH B 502 MANASMOTI APT GOREGAON East

Mumbai 400097 MAHARASHTRA Cert. No. MC-2010

SRL Ltd

PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL

ESTATE, S.V. ROAD, GOREGAON (W)

Mumbai, 400062 MAHARASHTRA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956

PATIENT NAME: SINGRAY KORAH PATIENT ID: SINGM0808782

ACCESSION NO: 0002VK055472 AGE: 44 Years SEX: Male ABHA NO:

DRAWN: 26/11/2022 08:52:50 RECEIVED: 26/11/2022 08:54:36 REPORTED: 29/11/2022 15:05:40

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

CELENT FAILENT ID.		
Results	Biological Reference Interval	Units
NORMAL		
NORMAL		
NORMAL		
NORMAL		
NORMAL		
NORMAL		
	NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL	Results Biological Reference Interval NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL NORMAL

NORMAL

DISTANT VISION RIGHT EYE WITHOUT GLASSES

REDUCE VISUAL ACUITY (6/9)

REAR VISION RIGHT EYE WITHOUT GLASSES

REDUCE VISUAL ACUITY (6/9)

REAR VISION RIGHT EYE WITHOUT GLASSES

REDUCE VISUAL ACUITY (N10)

REAR VISION LEFT EYE WITHOUT GLASSES

COLOUR VISION NORMAL (17/17)

* BASIC ENT EXAMINATION

EXTERNAL EAR CANAL NORMAL TYMPANIC MEMBRANE NORMAL

NOSE NO ABNORMALITY DETECTED

SINUSES NORMAL

THROAT NO ABNORMALITY DETECTED

TONSILS NOT ENLARGED

* BASIC DENTAL EXAMINATION

TEETH NORMAL GUMS HEALTHY

* SUMMARY

CORNEA

RELEVANT HISTORY NOT SIGNIFICANT RELEVANT GP EXAMINATION FINDINGS NOT SIGNIFICANT



Page 13 Of 18







CODE: C000138400

NAME AND ADDRESS:

SINGRAY KORAH

B 502 MANASMOTI APT GOREGAON East

Mumbai 400097 MAHARASHTRA

Cert. No. MC-2010

SRL Ltd

PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL

ESTATE, S.V. ROAD, GOREGAON (W)

Mumbai, 400062 MAHARASHTRA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956

PATIENT NAME: SINGRAY KORAH PATIENT ID: SINGM0808782

ACCESSION NO: 0002VK055472 AGE: 44 Years SEX: Male ABHA NO:

DRAWN: 26/11/2022 08:52:50 RECEIVED: 26/11/2022 08:54:36 REPORTED: 29/11/2022 15:05:40

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status **Final** Results Biological Reference Interval Units

RELEVANT LAB INVESTIGATIONS LOW HAEMOGLOBIN (12)

LOW PLATELET COUNT (100) LOW HDL CHOLESTEROL (34) RAISED LDL CHOLESTEROL (115)

RAISED NON HDL (133) RAISED SGPT (46) LOW T3 (77.7) RAISED T4 (4.03) RAISED TSH (10.200)

RELEVANT NON PATHOLOGY DIAGNOSTICS USG-NO ABNORMALITIES DETECTED

REMARKS / RECOMMENDATIONS LOW HAEMOGLOBIN, LOW WBC COUNT, LOW PLATELET COUNT, LOW HDL

CHOLESTEROL, RAISED TSH OMEGA 3 FATS SUPPLEMENT

VITAMIN D LEVELS

MONITOR THYROID FUNCTION TEST FOLLOW UP WITH PHYSICIAN











CODE: C000138400

NAME AND ADDRESS:

SINGRAY KORAH B 502 MANASMOTI APT GOREGAON East

Mumbai 400097 MAHARASHTRA

Cert. No. MC-2010

SRL Ltd PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W)

Mumbai, 400062 MAHARASHTRA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956

PATIENT NAME: SINGRAY KORAH PATIENT ID: SINGM0808782

ACCESSION NO: 0002VK055472 AGE: 44 Years SEX: Male ABHA NO:

DRAWN: 26/11/2022 08:52:50 RECEIVED: 26/11/2022 08:54:36 29/11/2022 15:05:40 REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Units Final

MEDI WHEEL FULL BODY HEALTH CHECK UP ABOVE 40 MALE

* ULTRASOUND ABDOMEN

ULTRASOUND ABDOMEN

NO ABNORMALITIES DETECTED

Interpretation(s)

BLOOD COUNTS, EDTA WHOLE BLOOD-The cell morphology is well preserved for 24hrs. However after 24-48 hrs a progressive increase in MCV and HCT is observed leading to a decrease in MCHC. A direct smear is recommended for an accurate differential count and for examination of RBC morphology

RBC AND PLATELET INDICES-Mentzer index (MCV/RBC) is an automated cell-counter based calculated screen tool to differentiate cases of Iron deficiency anaemia(>13) from Beta thalassaemia trait

(<13) in patients with microcytic anaemia. This needs to be interpreted in line with clinical correlation and suspicion. Estimation of HbA2 remains the gold standard for diagnosing a case of beta thalassaemia trait.

WBC DIFFERENTIAL COUNT-The optimal threshold of 3.3 for NLR showed a prognostic possibility of clinical symptoms to change from mild to severe in COVID positive patients. When age = 49.5 years old and NLR = 3.3, 46.1% COVID-19 patients with mild disease might become severe. By contrast, when age < 49.5 years old and NLR = 3.4 to 10.0 covid and NLR = 3.5 years old and NLR = 3.5 years old

3.3, COVID-19 patients tend to show mild disease.

(Reference to - The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients ; A.-P. Yang, et al.; International Immunopharmacology 84 (2020) 106504 This ratio element is a calculated parameter and out of NABL scope.

ERYTHROCYTE SEDIMENTATION RATE (ESR), WHOLE BLOOD-**TEST DESCRIPTION**:
Erythrocyte sedimentation rate (ESR) is a test that indirectly measures the degree of inflammation present in the body. The test actually measures the rate of fall

(sedimentation) of erythrocytes in a sample of blood that has been placed into a tall, thin, vertical tube. Results are reported as the millimetres of clear fluid (plasma) that are present at the top portion of the tube after one hour. Nowadays fully automated instruments are available to measure ESR.

ESR is not diagnostic; it is a non-specific test that may be elevated in a number of different conditions. It provides general information about the presence of an inflammatory condition.CRP is superior to ESR because it is more sensitive and reflects a more rapid change.

TEST INTERPRETATION

Increase in: Infections, Vasculities, Inflammatory arthritis, Renal disease, Anemia, Malignancies and plasma cell dyscrasias, Acute allergy Tissue injury, Pregnancy,

Estrogen medication, Aging.
Finding a very accelerated ESR(>100 mm/hour) in patients with ill-defined symptoms directs the physician to search for a systemic disease (Paraproteinemias,

Disseminated malignancies, connective tissue disease, severe infections such as bacterial endocarditis).

In pregnancy BRI in first trimester is 0-48 mm/hr(62 if anemic) and in second trimester (0-70 mm /hr(95 if anemic). ESR returns to normal 4th week post partum.

Decreased in: Polycythermia vera, Sickle cell anemia

LIMITATIONS

False elevated ESR: Increased fibrinogen, Drugs(Vitamin A, Dextran etc), Hypercholesterolemia

False Decreased: Poikilocytosis, (SickleCells, spherocytes), Microcytosis, Low fibrinogen, Very high WBC counts, Drugs (Quinine, salicylates)

1. Nathan and Oski's Haematology of Infancy and Childhood, 5th edition; 2. Paediatric reference intervals. AACC Press, 7th edition. Edited by S. Soldin; 3. The reference for the adult reference range is "Practical Haematology by Dacie and Lewis,10th edition. GLYCOSYLATED HEMOGLOBIN(HBA1C), EDTA WHOLE BLOOD-**Used For**:

- 1. Evaluating the long-term control of blood glucose concentrations in diabetic patients.
- 2.Diagnosing diabetes.
- 3. Identifying patients at increased risk for diabetes (prediabetes).

The ADA recommends measurement of HbA1c (typically 3-4 times per year for type 1 and poorly controlled type 2 diabetic patients, and 2 times per year for ne ADA recommends measurement of ADATE (typically 3-4 times per year not type 1 and poorly controlled type 2 diabetic patients) to determine whether a patients metabolic control has remained continuously within the target range.

1.eAG (Estimated average glucose) converts percentage HbA1c to md/dl, to compare blood glucose levels.

2. eAG gives an evaluation of blood glucose levels for the last couple of months.

3. eAG is calculated as eAG (mg/dl) = 28.7 * HbA1c - 46.7

HbA1c Estimation can get affected due to :

I.Shortened Erythrocyte survival: Any condition that shortens erythrocyte survival or decreases mean erythrocyte age (e.g. recovery from acute blood loss,hemolytic anemia) will falsely lower HbA1c test results.Fructosamine is recommended in these patients which indicates diabetes control over 15 days.

II.Vitamin C & E are reported to falsely lower test results.(possibly by inhibiting glycation of hemoglobin.
III.Iron deficiency anemia is reported to increase test results. Hypertriglyceridemia, uremia, hyperbilirubinemia, chronic alcoholism, chronic ingestion of salicylates & opiates











CODE: C000138400

NAME AND ADDRESS:

SINGRAY KORAH B 502 MANASMOTI APT GOREGAON East

Mumbai 400097 MAHARASHTRA

Cert. No. MC-2010

SRL Ltd PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W) Mumbai, 400062

MAHARASHTRA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956

PATIENT NAME: SINGRAY KORAH PATIENT ID: SINGM0808782

ACCESSION NO: 0002VK055472 AGE: 44 Years SEX: Male ABHA NO:

DRAWN: 26/11/2022 08:52:50 RECEIVED: 26/11/2022 08:54:36 29/11/2022 15:05:40 REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Units Final

addiction are reported to interfere with some assay methods, falsely increasing results.

IV.Interference of hemoglobinopathies in HbA1c estimation is seen in

a.Homozygous hemoglobinopathy. Fructosamine is recommended for testing of HbA1c. b.Heterozygous state detected (D10 is corrected for HbS & HbC trait.)

c.HbF > 25% on alternate paltform (Boronate affinity chromatography) is recommended for testing of HbA1c.Abnormal Hemoglobin electrophoresis (HPLC method) is recommended for detecting a hemoglobinopathy GLUCOSE FASTING,FLUORIDE PLASMA-**TEST DESCRIPTION**

Normally, the glucose concentration in extracellular fluid is closely regulated so that a source of energy is readily available to tissues and sothat no glucose is excreted in the

urine.

Increased in Diabetes mellitus, Cushing's syndrome (10 – 15%), chronic pancreatitis (30%). Drugs:corticosteroids,phenytoin, estrogen, thiazides.

Pancreatic islet cell disease with increased insulin,insulinoma,adrenocortical insufficiency, hypopituitarism,diffuse liver disease, malignancy (adrenocortical, stomach,fibrosarcoma), infant of a diabetic mother, enzyme deficiency diseases(e.g., galactosemia),Drugs- insulin,

ethanol, propranolol; sulfonylureas,tolbutamide, and other oral hypoglycemic agents

NOTE:

Hypoglycemia is defined as a glucoseof < 50 mg/dL in men and < 40 mg/dL in women.

While random serum glucose levels correlate with home glucose monitoring results (weekly mean capillary glucose values), there is wide fluctuation within individuals. Thus, glycosylated hemoglobin(HbA1c) levels are favored to monitor glycemic control.

High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.

GLUCOSE, POST-PRANDIAL, PLASMA-High fasting glucose level in comparison to post prandial glucose level may be seen due to effect of Oral Hypoglycaemics & Insulin treatment, Renal Glyosuria, Glycaemic index & response to food consumed, Alimentary Hypoglycemia, Increased insulin response & sensitivity etc.Additional test HbA1c LIVER FUNCTION PROFILE, SERUM-

LIVER FUNCTION PROFILE

Bilirubin is a yellowish pigment found in bile and is a breakdown product of normal heme catabolism. Bilirubin is excreted in bile and urine, and elevated levels may give yellow discoloration in jaundice. Elevated levels results from increased bilirubin production (eg, hemolysis and ineffective erythropoiesis), decreased bilirubin excretion (eg, obstruction and hepatitis), and abnormal bilirubin metabolism (eg, hereditary and neonatal jaundice). Conjugated (direct) bilirubin is elevated more than unconjugated (indirect) bilirubin in Viral hepatitis, Drug reactions, Alcoholic liver disease Conjugated (direct) bilirubin is also elevated more than unconjugated (indirect) bilirubin when there is some kind of blockage of the bile ducts like in Gallstones getting into the bile ducts, tumors &Scarring of the bile ducts. Increased unconjugated (indirect) bilirubin may be a result of Hemolytic or pernicious anemia, Transfusion reaction & a common metabolic condition termed Gilbert syndrome, due to low levels of the enzyme that attaches sugar molecules to bilirubin.

AST is an enzyme found in various parts of the body. AST is found in the liver, heart, skeletal muscle, kidneys, brain, and red blood cells, and it is commonly measured clinically as a marker for liver health. AST levels increase during chronic viral hepatitis, blockage of the bile duct, cirrhosis of the liver, liver cancer, kidney failure, hemolytic anemia,pancreatitis,hemochromatosis. AST levels may also increase after a heart attack or strenuous activity.ALT test measures the amount of this enzyme in the blood.ALT is found mainly in the liver, but also in smaller amounts in the kidneys,heart,muscles, and pancreas.It is commonly measured as a part of a diagnostic evaluation of hepatocellular injury, to determine liver health.AST levels increase during acute hepatitis,sometimes due to a viral infection,ischemia to the liver,chronic hepatitis, obstruction of bile ducts, cirrhosis,

ALP is a protein found in almost all body tissues. Tissues with higher amounts of ALP include the liver, bile ducts and bone. Elevated ALP levels are seen in Biliary obstruction, Osteoblastic bone tumors, osteomalacia, hepatitis, Hyperparathyroidism, Leukemia, Lymphoma, Paget's disease, Rickets, Sarcoidosis etc. Lower-than-normal ALP levels seen in Hypophosphatasia, Malnutrition, Protein deficiency, Wilson's disease. GGT is an enzyme found in cell membranes of many tissues mainly in the liver, kidney and pancreas. It is also found in other tissues including intestine, spleen, heart, brain and seminal vesicles. The highest concentration is in the kidney, but the liver is considered the source of normal enzyme activity. Serum GGT has been widely used as an index of liver dysfunction. Elevated serum GGT activity can be found in diseases of the liver, biliary system and pancreas. Conditions that increase serum GGT are obstructive liver disease, high alcohol consumption and use of enzyme-inducing drugs etc. Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and globulin. Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease. Lower-than-normal levels may be due to: Agammaglobulinemia,Bleeding (hemorrhage),Burns,Glomerulonephritis,Liver disease, Malabsorption,Malnutrition,Nephrotic syndrome,Protein-losing enteropathy etc.Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular

permeability or decreased lymphatic clearance,malnutrition and wasting etc
BLOOD UREA NITROGEN (BUN), SERUM-Causes of Increased levels include Pre renal (High protein diet, Increased protein catabolism, GI haemorrhage, Cortisol, Dehydration, CHF Renal), Renal Failure, Post Renal (Malignancy, Nephrolithiasis, Prostatism)
Causes of decreased level include Liver disease, SIADH.
CREATININE, SERUM-Higher than normal level may be due to:

- Blockage in the urinary tract
 Kidney problems, such as kidney damage or failure, infection, or reduced blood flow
- Loss of body fluid (dehydration)
 Muscle problems, such as breakdown of muscle fibers
- Problems during pregnancy, such as seizures (eclampsia)), or high blood pressure caused by pregnancy (preeclampsia)

Lower than normal level may be due to:

- Myasthenia GravisMuscular dystrophy



Page 16 Of 18









CODE: C000138400

NAME AND ADDRESS:

SINGRAY KORAH B 502 MANASMOTI APT GOREGAON East

Mumbai 400097 MAHARASHTRA

Cert. No. MC-2010

SRL Ltd PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL ESTATE, S.V. ROAD, GOREGAON (W)

Mumbai, 400062 MAHARASHTRA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956

PATIENT NAME: SINGRAY KORAH PATIENT ID: SINGM0808782

ACCESSION NO: 0002VK055472 AGE: 44 Years SEX: Male ABHA NO:

DRAWN: 26/11/2022 08:52:50 RECEIVED: 26/11/2022 08:54:36 29/11/2022 15:05:40 REPORTED:

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Results Units Final

URIC ACID, SERUM-

Causes of Increased levels:-Dietary(High Protein Intake,Prolonged Fasting,Rapid weight loss),Gout,Lesch nyhan syndrome,Type 2 DM,Metabolic syndrome Causes of decreased levels-Low Zinc intake, OCP, Multiple Sclerosis

TOTAL PROTEIN, SERUM-

Serum total protein, also known as total protein, is a biochemical test for measuring the total amount of protein in serum. Protein in the plasma is made up of albumin and alobulin

Higher-than-normal levels may be due to: Chronic inflammation or infection, including HIV and hepatitis B or C, Multiple myeloma, Waldenstrom's disease Lower-than-normal levels may be due to: Agammaglobulinemia, Bleeding (hemorrhage), Burns, Glomerulonephritis, Liver disease, Malabsorption, Malnutrition, Nephrotic syndrome, Protein-losing enteropathy etc.

Human serum albumin is the most abundant protein in human blood plasma. It is produced in the liver. Albumin constitutes about half of the blood serum protein. Low blood albumin levels (hypoalbuminemia) can be caused by: Liver disease like cirrhosis of the liver, nephrotic syndrome, protein-losing enteropathy, Burns, hemodilution, increased vascular permeability or decreased lymphatic clearance, malnutrition and wasting etc.

ABO GROUP & RH TYPE, EDTA WHOLE BLOODBlood group is identified by antigens and antibodies present in the blood. Antigens are protein molecules found on the surface of red blood cells. Antibodies are found in plasma. To determine blood group, red cells are mixed with different antibody solutions to give A,B,O or AB.

Disclaimer: "Please note, as the results of previous ABO and Rh group (Blood Group) for pregnant women are not available, please check with the patient records for availability of the same.

The test is performed by both forward as well as reverse grouping methods.

MEDICAL

THIS REPORT CARRIES THE SIGNATURE OF OUR LABORATORY DIRECTOR. THIS IS AN INVIOLABLE FEATURE OF OUR LAB MANAGEMENT SOFTWARE. HOWEVER, ALL

EXAMINATIONS AND INVESTIGATIONS HAVE BEEN CONDUCTED BY OUR PANEL OF DOCTORS.

End Of Report

Please visit www.srlworld.com for related Test Information for this accession TEST MARKED WITH '*' ARE OUTSIDE THE NABL ACCREDITED SCOPE OF THE LABORATORY.

Dr. J N Shukla , MBBS, AFIH **Consultant Physician**

Dr. Ekta Patil, MD (Reg.No. MMC2008/04/1142) **Senior Microbiologist**

Dr. Sushant Chikane **Consultant Pathologist**

Dr. Sneha Wadalkar, M.D. (Reg.no.MMC2012/06/1868) **Junior Biochemist**





Page 17 Of 18







CODE: C000138400

NAME AND ADDRESS:

SINGRAY KORAH B 502 MANASMOTI APT GOREGAON East

Mumbai 400097 MAHARASHTRA Cert. No. MC-2010

SRL Ltd

PRIME SQUARE BUILDING, PLOT NO 1, GAIWADI INDUSTRIAL

ESTATE, S.V. ROAD, GOREGAON (W)

Mumbai, 400062 MAHARASHTRA, INDIA Tel: 9111591115, Fax:

CIN - U74899PB1995PLC045956

PATIENT NAME: SINGRAY KORAH PATIENT ID: SINGM0808782

ACCESSION NO: 0002VK055472 AGE: 44 Years SEX: Male ABHA NO:

DRAWN: 26/11/2022 08:52:50 RECEIVED: 26/11/2022 08:54:36 REPORTED: 29/11/2022 15:05:40

REFERRING DOCTOR: SELF CLIENT PATIENT ID:

Test Report Status Final Results Units

CONDITIONS OF LABORATORY TESTING & REPORTING

- 1. It is presumed that the test sample belongs to the patient named or identified in the test requisition form.
- 2. All tests are performed and reported as per the turnaround time stated in the SRL Directory of Services.
- 3. Result delays could occur due to unforeseen circumstances such as non-availability of kits / equipment breakdown / natural calamities / technical downtime or any other unforeseen event.
- 4. A requested test might not be performed if:
 - i. Specimen received is insufficient or inappropriate
 - ii. Specimen quality is unsatisfactory
 - iii. Incorrect specimen type
 - iv. Discrepancy between identification on specimen container label and test requisition form

- 5. SRL confirms that all tests have been performed or assayed with highest quality standards, clinical safety & technical integrity.
- 6. Laboratory results should not be interpreted in isolation; it must be correlated with clinical information and be interpreted by registered medical practitioners only to determine final diagnosis.
- 7. Test results may vary based on time of collection, physiological condition of the patient, current medication or nutritional and dietary changes. Please consult your doctor or call us for any clarification.
- 8. Test results cannot be used for Medico legal purposes.
- 9. In case of queries please call customer care (91115 91115) within 48 hours of the report.

SRL Limited

Fortis Hospital, Sector 62, Phase VIII, Mohali 160062



